A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects with untreated aggressive B-cell lymphoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506094-35-00

Acronym

CC-220-DLBCL-001

Enrollment

112

Registered

2023-09-15

Start date

2021-09-17

Completion date

Unknown

Last updated

2025-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Newly diagnosed aggressive B-cell lymphoma (a-BCL)

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Greece, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026